home / stock / kaltf / kaltf news

KALTF News and Press, Kalytera Therapeutics From 12/20/21

Stock Information
Company Name: Kalytera Therapeutics
Stock Symbol: KALTF
Market: OTC
Website: kalytera.co
Menu
KALTF KALTF Quote KALTF Short KALTF News KALTF Articles KALTF Message Board
Get KALTF Alerts

News, Short Squeeze, Breakout and More Instantly...
KALTF - Claritas Announces Publication of Peer-Reviewed Article Reporting that R-107 Significantly Improved Multi-Organ Function and Survival in an Ovine (Sheep) Model of Sepsis

SAN FRANCISCO and TORONTO, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that the journal Scientific Reports, has published a peer-reviewed article reporting that R-107, t...
KALTF - Claritas inks new partnership with Scientia for early-stage study for R-107

Claritas Pharmaceuticals (OTCPK:KALTF) announced it has ended its partnership with CMAX Clinical Research for a Phase 1 study on R-107, the company’s experimental liquid, nitric oxide-releasing compound. The company has inked a clinical trial research agreement with Australia-based Sci...

KALTF - Claritas Provides Update Regarding Phase 1 Clinical Study

SAN FRANCISCO and TORONTO, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today provided an update regarding the expected time to completion of its Phase 1 clinical study of R-107, the Company...

KALTF - Claritas Announces Engagement of B. Riley Securities as Sponsor for the Company's Planned Up-Listing of its Securities to the OTCQB

SAN FRANCISCO and TORONTO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: CLAS.V) (the " Company " or " Claritas ") today announced the engagement of B. Riley Securities, Inc. ( “B. Riley Securities” ) as its exclusive ...
KALTF - Claritas Announces Closing of Convertible Debenture Financing with Obsidian Global GP, LLC

SAN FRANCISCO, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: CLAS.V) (the " Company " or " Claritas ") is pleased to announce that it has closed the first tranche of a private placement offering (the “ Offering ”) of c...

KALTF - Claritas Announces Option to Acquire Rights to Novel Drug for Treatment of COVID-19 Related ARDS

SAN FRANCISCO and TORONTO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: CLAS.V) (the " Company " or " Claritas ") today announced that it has entered into a binding Letter of Intent (the “LOI” ) with Biozeus Biopharm...

KALTF - Claritas Announces Proposed Financing with Obsidian Global GP, LLC, Receipt of Australian Tax Credit, and Start of Phase 1 Clinical Study of R-107

SAN FRANCISCO and TORONTO, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTD) (the " Company " or " Claritas ") is pleased to announce that, subject to TSXV approval, it will close the first tranche of a brokered private placement off...
KALTF - Claritas Announces Grant of Stock Options to Directors and Officers

SAN FRANCISCO, July 27, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") announced that it granted stock options on July 23, 2021 to the directors and officers of the Company. The stock options have...

KALTF - Claritas says a new study validates potential of its COVID-19 therapy

BlackJack3D/E+ via Getty Images Claritas Pharmaceuticals (KALTF) has added ~13.3% in the pre-market after the company announced a recent publication of a study validating its nitric oxide-releasing compound, R-107, as a potential therapy against COVID-19. The study conducted by...

KALTF - Claritas Cites Data from Study Demonstrating Effectiveness of Nitric Oxide in Patients with Severe COVID-19 Pneumonia as Validation of the Company's Nitric Oxide-Releasing Compound, R-107

SAN FRANCISCO and TORONTO, July 26, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that a recently published study led by clinicians at Royal Brompton & Harefield NHS Foundation Trust ...
Previous 10 Next 10